Literature DB >> 8760304

Distinct p53-mediated G1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents.

T S Huang1, M L Kuo, J Y Shew, Y W Chou, W K Yang.   

Abstract

N3T3 and P-3T3 cells, originally isolated from a NIH3T3 cell clone on the basis of their negative and positive transformation by v-Abl, v-Src and Bcr-Abl, were previously found to show distinct cyclin activity changes following 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, which is anti-mitogenic for N-3T3 cells and mitogenic for P-3T3 cells. We have found in this study that, while the G1/S arrest and cell death induced by serum starvation and TPA treatment in N-3T3 cells did not involve p53-mediated checkpoint or apoptosis, N-3T3 and P-3T3 cells evidently responded differently in these aspects of cell cycle regulation to DNA-damaging agents, methylmethane sulfonate (MMS) and gamma-radiation. In N-3T3 cells, DNA damages elicit cell growth arrest at G1/S transition with concomitant accumulation of p53 and p53-inducible Waf1/Cip1 proteins and also signs of apoptosis such as DNA ladder patterns and apoptotic (subgenomic) peak in flow cytograph. Conversely, P-3T3 cells treated with the DNA-damaging agents showed no cell cycle interruption nor accumulation of p53 or Waf1/Cip1. However, both P-3T3 and N-3T3 cells showed the same p53 protein half-life of 40 min or less, the same wild-type p53 DNA sequence and the same co-immunoprecipitable cellular proteins in complexes with p53, suggesting that an alteration in a signal transduction pathway upstream of p53 might account for the evasion of p53-mediated G1 checkpoint in P-3T3 cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760304

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  RACK1 regulates G1/S progression by suppressing Src kinase activity.

Authors:  Vidya Mamidipudi; Jian Zhang; Kelly C Lee; Christine A Cartwright
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 2.  c-Abl in neurodegenerative disease.

Authors:  Sarah D Schlatterer; Christopher M Acker; Peter Davies
Journal:  J Mol Neurosci       Date:  2011-07-05       Impact factor: 3.444

3.  p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.

Authors:  X Zou; F Cong; M Coutts; G Cattoretti; S P Goff; K Calame
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif.

Authors:  Andrew R Tee; Christopher G Proud
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

5.  Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals.

Authors:  Yaara Zwang; Aldema Sas-Chen; Yotam Drier; Tal Shay; Roi Avraham; Mattia Lauriola; Efrat Shema; Efrat Lidor-Nili; Jasmine Jacob-Hirsch; Ninette Amariglio; Yiling Lu; Gordon B Mills; Gideon Rechavi; Moshe Oren; Eytan Domany; Yosef Yarden
Journal:  Mol Cell       Date:  2011-05-20       Impact factor: 17.970

6.  Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis.

Authors:  N Ahmad; D K Feyes; R Agarwal; H Mukhtar
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

Review 7.  Cell cycle control, checkpoint mechanisms, and genotoxic stress.

Authors:  R E Shackelford; W K Kaufmann; R S Paules
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

8.  Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation.

Authors:  Tien-Jyun Chang; Hsing-Chi Tseng; Meng-Wei Liu; Yi-Cheng Chang; Meng-Lun Hsieh; Lee-Ming Chuang
Journal:  Sci Rep       Date:  2016-03-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.